Whole-Genome Reconstruction and Mutational Signatures in Gastric

Total Page:16

File Type:pdf, Size:1020Kb

Whole-Genome Reconstruction and Mutational Signatures in Gastric Nagarajan et al. Genome Biology 2012, 13:R115 http://genomebiology.com/2012/13/12/R115 RESEARCH Open Access Whole-genome reconstruction and mutational signatures in gastric cancer Niranjan Nagarajan1*†, Denis Bertrand1†, Axel M Hillmer2†, Zhi Jiang Zang3,4†, Fei Yao2,5, Pierre-Étienne Jacques1, Audrey SM Teo2, Ioana Cutcutache6, Zhenshui Zhang2, Wah Heng Lee1, Yee Yen Sia2, Song Gao7, Pramila N Ariyaratne1, Andrea Ho2, Xing Yi Woo1, Lavanya Veeravali8, Choon Kiat Ong9, Niantao Deng10, Kartiki V Desai11, Chiea Chuen Khor4,12, Martin L Hibberd4,12, Atif Shahab8, Jaideepraj Rao13, Mengchu Wu14, Ming Teh15, Feng Zhu16, Sze Yung Chin15, Brendan Pang14,15, Jimmy BY So17, Guillaume Bourque18,19, Richie Soong14,15, Wing-Kin Sung1, Bin Tean Teh9, Steven Rozen6, Xiaoan Ruan2, Khay Guan Yeoh16, Patrick BO Tan10,12,14* and Yijun Ruan2,20* Abstract Background: Gastric cancer is the second highest cause of global cancer mortality. To explore the complete repertoire of somatic alterations in gastric cancer, we combined massively parallel short read and DNA paired-end tag sequencing to present the first whole-genome analysis of two gastric adenocarcinomas, one with chromosomal instability and the other with microsatellite instability. Results: Integrative analysis and de novo assemblies revealed the architecture of a wild-type KRAS amplification, a common driver event in gastric cancer. We discovered three distinct mutational signatures in gastric cancer - against a genome-wide backdrop of oxidative and microsatellite instability-related mutational signatures, we identified the first exome-specific mutational signature. Further characterization of the impact of these signatures by combining sequencing data from 40 complete gastric cancer exomes and targeted screening of an additional 94 independent gastric tumors uncovered ACVR2A, RPL22 and LMAN1 as recurrently mutated genes in microsatellite instability-positive gastric cancer and PAPPA as a recurrently mutated gene in TP53 wild-type gastric cancer. Conclusions: These results highlight how whole-genome cancer sequencing can uncover information relevant to tissue-specific carcinogenesis that would otherwise be missed from exome-sequencing data. Background salt diet, smoking, and infection by Helicobacter pylori Gastric cancer (GC) is the fourth most common cancer [1]. Understanding the mutational impact of these envir- and the second leading cause of cancer death worldwide. onmental exposures on the genomes of gastric epithelial Early stage GC is often asymptomatic or associated with cells is essential to shed light on specific genes and non-specific symptoms, resulting in most patients pre- pathways associated with gastric tumorigenesis. senting at advanced disease stages. Treatment options Previous studies in lung cancer [2,3], melanoma [4], for late-stage GC patients are limited, with surgery and and leukemia [5] have shown that environmental carci- chemotherapy regimens offering modest survival bene- nogens and drugs can elicit specific somatic mutational fits. Environmental risk factors for GC include a high profiles in cancer genomes, referred to as ‘mutational signatures’. While previous studies on GC have applied * Correspondence: [email protected]; [email protected]; exome-sequencing approaches to identify frequently [email protected] mutated genes [6,7], identifying mutational signatures is † Contributed equally best done using whole-genome data, due to its comple- 1Computational and Systems Biology, Genome Institute of Singapore, Singapore 138672, Singapore teness and ability to simultaneously uncover micro- and 2Genome Technology and Biology, Genome Institute of Singapore, macro-scale somatic alterations. In this study, we sought Singapore 138672, Singapore toprovideamorecomprehensiveunderstandingof Full list of author information is available at the end of the article © 2012 et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Nagarajan et al. Genome Biology 2012, 13:R115 Page 2 of 10 http://genomebiology.com/2012/13/12/R115 mutational processes in GC by analyzing whole-genome Table 1 Somatic variations in two GC tumors identified sequences of two GCs and their matched-normal con- by whole genome sequencing approaches trols, using both short-read (SR) next-generation Patient ID NGCII082 NGCII092 sequencing and a long insert (approximately 10 kbp) SNVs, all somatic 14,856 17,473 DNA paired-end tag (DNA-PET) protocol [8]. We also Coding regions 119 116 sought to explore the combination of these datasets for Non-synonymous 86 73 de novo assembly of cancer and normal genomes and to Promoter regions 101 161 comprehensively catalogue a range of (point mutations Indels, all somatic 11,738 2,486 to megabase-sized) somatic alterations in the tumor. Coding regions 12 2 Finally, we used this catalogue to characterize the CNVs, all somatic 836 21,776 impact of mutational processes on genes and used a Affecting genes 3 265 screening approach to validate recurrently mutated SVs, all somatic 12 146 genes in subtypes of GC defined by specific mutational Affecting genes 11 96 processes. Deletions 6 56 Tandem duplications 2 8 Results Unpaired inversions 0 26 Integrative short read/DNA-PET analysis and de novo Inversions 0 2 assembly Insertions (intra-chromosomal) 0 0 The matched tumor and normal samples analyzed were Insertions (inter-chromosomal) 0 0 from two Singaporean patients. One GC exhibited evi- Isolated translocations 0 3 dence of microsatellite instability (MSI) and active H. Balanced translocations 0 0 pylori infection (see Table S1 in Additional file 1 for other Complex events (intra- chromosomal) 4 49 clinical characteristics). Each tumor and matched normal Complex events (inter- chromosomal) 0 2 sample was sequenced to more than 30-fold average base pair coverage by Illumina SR sequencing (Materials and methods; Table S2 in Additional file 1), and to > 130-fold were unable to identify nearly half of the validated SVs physical coverage using large-insert (approximately 10 and fusions genes; Note 1 in Additional file 1). For exam- kbp) DNA-PET sequencing [9] on the SOLiD platform ple, NGCII092 exhibited a focal genomic amplification on (Materials and methods; Table S3 and Note 1 in Addi- chromosome 12p11-12 in a region containing the wild- tional file 1). Single nucleotide variants (SNVs) and short type KRAS gene, a genomic event frequently observed in insertions and deletions (indels) from tumor and normal GC [10]. The combined SR/DNA-PET data (Materials and genomes were combined to identify somatic variants methods) enabled a detailed putative reconstruction of the (Table 1 and Materials and methods) and reliability of evolutionary lineage of the amplified KRAS locus with somatic calls was confirmed using targeted sequencing concomitant deletion of a proposed tumor suppressor (validation rate of 90% for SNVs and 96% for indels; Mate- gene RASSF8 (as well as another focal amplicon at chro- rials and methods). SR and DNA-PET data were also used mosome 6p) as described in the supplementary text to identify somatic copy-number variations (CNVs) and (Figure 1; Figures S1 and S2 and Note 3 in Additional file structural variations (SVs) (validation rate = 81%; Materi- 1). Reconstruction of the tumor genomes also allowed the als and methods; Note 1 in Additional file 1). prediction of fusion genes and complex rearrangements We integrated the SR and DNA-PET sequence informa- that resemble patterns created by replication coupled tion to perform de novo assembly of the tumor and nor- mechanisms [11] and are further described in the supple- mal genomes. While complete de novo assembly of a mentary text (Note 4 and Figures S3 and S4 in Additional tumor genome still poses significant technical challenges file 1 and Table S6 in Additional file 2). and has not been attempted before, we were able to use Second, a combined SR/DNA-PET analysis allowed us the SR/DNA-PET data to construct highly contiguous to assemble sequences present in the tumor genome but draft assemblies of median scaffold lengths (N50) in the not in the reference human genome. For example, in range of 41 to 148 kb, with DNA-PET data assisting in tri- patient NGCII082 exhibiting active H. pylori infection, pling sequence contiguity of the assemblies (Materials and we detected approximately 2,000 short-sequence reads methods; Note 2 and Table S5 in Additional file 1). Impor- and > 600 DNA-PET tags corresponding to the H. pylori tantly, performing de novo SR/DNA-PET assembly genome (the first such report for a bacterial pathogen revealed several findings not observed using conventional from tumor sequencing), in addition to a tumor-asso- analyses of the SR data. First, the de novo approach ciated microbiome (these were not seen in NGCII092; allowed for characterization of large-scale somatic struc- see Figure S5 and Note 5 in Additional file 1 for details). tural variations at single base-pair resolution (SR libraries Note that, despite being fewer in number, the DNA-PET Nagarajan et al. Genome Biology 2012, 13:R115 Page 3 of 10 http://genomebiology.com/2012/13/12/R115 (a) NGCII082 20 1 2 3 4 5 6 7 8 9 10 11 12 1314151617 19 21 X 18 20 22 15 10 Copy number 5 2 NGCII092 20 15 10 Copy number 5 2 (b) chr12 0M 10M 20M 30M 40M 50M 60M 70M 80M 90M 100M 110M 120M 130M 20 10 Copy number 0 chr12:17-34Mb 17M 18M 19M 20M 21M 22M 23M 24M 25M 26M 27M 28M 29M 30M 31M 32M 33M 34M KRAS 20 RASSF8 10 Copy number 0 Cluster size 0 45 57 50 61 76 100 129 150 127 122 200 250 282 300 (c) SOX5 OVCH1 OVCH1 SOX5 129_+24063846..24075698 129_+29495931..29508168 Figure 1 Copy number of two gastric cancer genomes, mechanism of 12p amplification and creation of a fusion gene.
Recommended publications
  • Regulation and Dysregulation of Chromosome Structure in Cancer
    Regulation and Dysregulation of Chromosome Structure in Cancer The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Hnisz, Denes et al. “Regulation and Dysregulation of Chromosome Structure in Cancer.” Annual Review of Cancer Biology 2, 1 (March 2018): 21–40 © 2018 Annual Reviews As Published https://doi.org/10.1146/annurev-cancerbio-030617-050134 Version Author's final manuscript Citable link http://hdl.handle.net/1721.1/117286 Terms of Use Creative Commons Attribution-Noncommercial-Share Alike Detailed Terms http://creativecommons.org/licenses/by-nc-sa/4.0/ Regulation and dysregulation of chromosome structure in cancer Denes Hnisz1*, Jurian Schuijers1, Charles H. Li1,2, Richard A. Young1,2* 1 Whitehead Institute for Biomedical Research, 455 Main Street, Cambridge, MA 02142, USA 2 Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA * Corresponding authors Corresponding Authors: Denes Hnisz Whitehead Institute for Biomedical Research 455 Main Street Cambridge, MA 02142 Tel: (617) 258-7181 Fax: (617) 258-0376 [email protected] Richard A. Young Whitehead Institute for Biomedical Research 455 Main Street Cambridge, MA 02142 Tel: (617) 258-5218 Fax: (617) 258-0376 [email protected] 1 Summary Cancer arises from genetic alterations that produce dysregulated gene expression programs. Normal gene regulation occurs in the context of chromosome loop structures called insulated neighborhoods, and recent studies have shown that these structures are altered and can contribute to oncogene dysregulation in various cancer cells. We review here the types of genetic and epigenetic alterations that influence neighborhood structures and contribute to gene dysregulation in cancer, present models for insulated neighborhoods associated with the most prominent human oncogenes, and discuss how such models may lead to further advances in cancer diagnosis and therapy.
    [Show full text]
  • Supplementary Information – Postema Et Al., the Genetics of Situs Inversus Totalis Without Primary Ciliary Dyskinesia
    1 Supplementary information – Postema et al., The genetics of situs inversus totalis without primary ciliary dyskinesia Table of Contents: Supplementary Methods 2 Supplementary Results 5 Supplementary References 6 Supplementary Tables and Figures Table S1. Subject characteristics 9 Table S2. Inbreeding coefficients per subject 10 Figure S1. Multidimensional scaling to capture overall genomic diversity 11 among the 30 study samples Table S3. Significantly enriched gene-sets under a recessive mutation model 12 Table S4. Broader list of candidate genes, and the sources that led to their 13 inclusion Table S5. Potential recessive and X-linked mutations in the unsolved cases 15 Table S6. Potential mutations in the unsolved cases, dominant model 22 2 1.0 Supplementary Methods 1.1 Participants Fifteen people with radiologically documented SIT, including nine without PCD and six with Kartagener syndrome, and 15 healthy controls matched for age, sex, education and handedness, were recruited from Ghent University Hospital and Middelheim Hospital Antwerp. Details about the recruitment and selection procedure have been described elsewhere (1). Briefly, among the 15 people with radiologically documented SIT, those who had symptoms reminiscent of PCD, or who were formally diagnosed with PCD according to their medical record, were categorized as having Kartagener syndrome. Those who had no reported symptoms or formal diagnosis of PCD were assigned to the non-PCD SIT group. Handedness was assessed using the Edinburgh Handedness Inventory (EHI) (2). Tables 1 and S1 give overviews of the participants and their characteristics. Note that one non-PCD SIT subject reported being forced to switch from left- to right-handedness in childhood, in which case five out of nine of the non-PCD SIT cases are naturally left-handed (Table 1, Table S1).
    [Show full text]
  • University of Bath Research Portal
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Bath Research Portal Citation for published version: Sherwood, V, Recino, A, Jeffries, A, Ward, A & Chalmers, AD 2010, 'The N-terminal RASSF family: a new group of Ras-association-domain-containing proteins, with emerging links to cancer formation', Biochemical Journal, vol. 425, no. 2, pp. 303-311. https://doi.org/10.1042/BJ20091318 DOI: 10.1042/BJ20091318 Publication date: 2010 Link to publication The final version of record is available at http://www.biochemj.org/bj/default.htm University of Bath General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 12. May. 2019 The N-terminal RASSF family; A new group of Ras association domain containing proteins, with emerging links to cancer formation. Victoria Sherwood *†, Asha Recino*, Alex Jeffries*, Andrew Ward*, Andrew D Chalmers*1. *, Centre for Regenerative Medicine, Department of Biology and Biochemistry, University of Bath, Bath, BA2 7AY, UK. †, Present address, Cell and Experimental Pathology, Lund University, Malmö University Hospital, S-205 02 MALMÖ, Sweden. 1, to whom correspondence should be addressed (e mail [email protected]). Running title: The N-terminal RASSF family and cancer.
    [Show full text]
  • Variation in Protein Coding Genes Identifies Information Flow
    bioRxiv preprint doi: https://doi.org/10.1101/679456; this version posted June 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Animal complexity and information flow 1 1 2 3 4 5 Variation in protein coding genes identifies information flow as a contributor to 6 animal complexity 7 8 Jack Dean, Daniela Lopes Cardoso and Colin Sharpe* 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Institute of Biological and Biomedical Sciences 25 School of Biological Science 26 University of Portsmouth, 27 Portsmouth, UK 28 PO16 7YH 29 30 * Author for correspondence 31 [email protected] 32 33 Orcid numbers: 34 DLC: 0000-0003-2683-1745 35 CS: 0000-0002-5022-0840 36 37 38 39 40 41 42 43 44 45 46 47 48 49 Abstract bioRxiv preprint doi: https://doi.org/10.1101/679456; this version posted June 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Animal complexity and information flow 2 1 Across the metazoans there is a trend towards greater organismal complexity. How 2 complexity is generated, however, is uncertain. Since C.elegans and humans have 3 approximately the same number of genes, the explanation will depend on how genes are 4 used, rather than their absolute number.
    [Show full text]
  • ASPP Proteins Discriminate Between PP1 Catalytic Subunits Through Their SH3 Domain and the PP1 C-Tail
    ARTICLE https://doi.org/10.1038/s41467-019-08686-0 OPEN ASPP proteins discriminate between PP1 catalytic subunits through their SH3 domain and the PP1 C-tail M. Teresa Bertran1, Stéphane Mouilleron 2, Yanxiang Zhou1, Rakhi Bajaj3, Federico Uliana4, Ganesan Senthil Kumar3, Audrey van Drogen4, Rebecca Lee2, Jennifer J. Banerjee1, Simon Hauri4, Nicola O’Reilly 5, Matthias Gstaiger4, Rebecca Page3, Wolfgang Peti3 & Nicolas Tapon 1 1234567890():,; Serine/threonine phosphatases such as PP1 lack substrate specificity and associate with a large array of targeting subunits to achieve the requisite selectivity. The tumour suppressor ASPP (apoptosis-stimulating protein of p53) proteins associate with PP1 catalytic subunits and are implicated in multiple functions from transcriptional regulation to cell junction remodelling. Here we show that Drosophila ASPP is part of a multiprotein PP1 complex and that PP1 association is necessary for several in vivo functions of Drosophila ASPP. We solve the crystal structure of the human ASPP2/PP1 complex and show that ASPP2 recruits PP1 using both its canonical RVxF motif, which binds the PP1 catalytic domain, and its SH3 domain, which engages the PP1 C-terminal tail. The ASPP2 SH3 domain can discriminate between PP1 isoforms using an acidic specificity pocket in the n-Src domain, providing an exquisite mechanism where multiple motifs are used combinatorially to tune binding affinity to PP1. 1 Apoptosis and Proliferation Control Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. 2 Structural Biology - Science Technology Platform, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. 3 Chemistry and Biochemistry Department, University of Arizona, 1041 E.
    [Show full text]
  • Agricultural University of Athens
    ΓΕΩΠΟΝΙΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΤΩΝ ΖΩΩΝ ΤΜΗΜΑ ΕΠΙΣΤΗΜΗΣ ΖΩΙΚΗΣ ΠΑΡΑΓΩΓΗΣ ΕΡΓΑΣΤΗΡΙΟ ΓΕΝΙΚΗΣ ΚΑΙ ΕΙΔΙΚΗΣ ΖΩΟΤΕΧΝΙΑΣ ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ Εντοπισμός γονιδιωματικών περιοχών και δικτύων γονιδίων που επηρεάζουν παραγωγικές και αναπαραγωγικές ιδιότητες σε πληθυσμούς κρεοπαραγωγικών ορνιθίων ΕΙΡΗΝΗ Κ. ΤΑΡΣΑΝΗ ΕΠΙΒΛΕΠΩΝ ΚΑΘΗΓΗΤΗΣ: ΑΝΤΩΝΙΟΣ ΚΟΜΙΝΑΚΗΣ ΑΘΗΝΑ 2020 ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ Εντοπισμός γονιδιωματικών περιοχών και δικτύων γονιδίων που επηρεάζουν παραγωγικές και αναπαραγωγικές ιδιότητες σε πληθυσμούς κρεοπαραγωγικών ορνιθίων Genome-wide association analysis and gene network analysis for (re)production traits in commercial broilers ΕΙΡΗΝΗ Κ. ΤΑΡΣΑΝΗ ΕΠΙΒΛΕΠΩΝ ΚΑΘΗΓΗΤΗΣ: ΑΝΤΩΝΙΟΣ ΚΟΜΙΝΑΚΗΣ Τριμελής Επιτροπή: Aντώνιος Κομινάκης (Αν. Καθ. ΓΠΑ) Ανδρέας Κράνης (Eρευν. B, Παν. Εδιμβούργου) Αριάδνη Χάγερ (Επ. Καθ. ΓΠΑ) Επταμελής εξεταστική επιτροπή: Aντώνιος Κομινάκης (Αν. Καθ. ΓΠΑ) Ανδρέας Κράνης (Eρευν. B, Παν. Εδιμβούργου) Αριάδνη Χάγερ (Επ. Καθ. ΓΠΑ) Πηνελόπη Μπεμπέλη (Καθ. ΓΠΑ) Δημήτριος Βλαχάκης (Επ. Καθ. ΓΠΑ) Ευάγγελος Ζωίδης (Επ.Καθ. ΓΠΑ) Γεώργιος Θεοδώρου (Επ.Καθ. ΓΠΑ) 2 Εντοπισμός γονιδιωματικών περιοχών και δικτύων γονιδίων που επηρεάζουν παραγωγικές και αναπαραγωγικές ιδιότητες σε πληθυσμούς κρεοπαραγωγικών ορνιθίων Περίληψη Σκοπός της παρούσας διδακτορικής διατριβής ήταν ο εντοπισμός γενετικών δεικτών και υποψηφίων γονιδίων που εμπλέκονται στο γενετικό έλεγχο δύο τυπικών πολυγονιδιακών ιδιοτήτων σε κρεοπαραγωγικά ορνίθια. Μία ιδιότητα σχετίζεται με την ανάπτυξη (σωματικό βάρος στις 35 ημέρες, ΣΒ) και η άλλη με την αναπαραγωγική
    [Show full text]
  • Nucleic Acids Research, 2009, Vol
    Published online 2 June 2009 Nucleic Acids Research, 2009, Vol. 37, No. 14 4587–4602 doi:10.1093/nar/gkp425 An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia Yair Benita1, Hirotoshi Kikuchi2, Andrew D. Smith3, Michael Q. Zhang3, Daniel C. Chung2 and Ramnik J. Xavier1,2,* 1Center for Computational and Integrative Biology, 2Gastrointestinal Unit, Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114 and 3Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA Received April 20, 2009; Revised May 6, 2009; Accepted May 8, 2009 ABSTRACT the pivotal mediators of the cellular response to hypoxia is hypoxia-inducible factor (HIF), a transcription factor The transcription factor Hypoxia-inducible factor 1 that contains a basic helix-loop-helix motif as well as (HIF-1) plays a central role in the transcriptional PAS domain. There are three known members of the response to oxygen flux. To gain insight into HIF family (HIF-1, HIF-2 and HIF-3) and all are a/b the molecular pathways regulated by HIF-1, it is heterodimeric proteins. HIF-1 was the first factor to be essential to identify the downstream-target genes. cloned and is the best understood isoform (1). HIF-3 is We report here a strategy to identify HIF-1-target a distant relative of HIF-1 and little is currently known genes based on an integrative genomic approach about its function and involvement in oxygen homeosta- combining computational strategies and experi- sis.
    [Show full text]
  • A Revised Nomenclature for the Human and Rodent Α-Tubulin Gene Family ⁎ Varsha K
    Genomics 90 (2007) 285–289 www.elsevier.com/locate/ygeno Short Communication A revised nomenclature for the human and rodent α-tubulin gene family ⁎ Varsha K. Khodiyar a, , Lois J. Maltais b, Katherine M.B. Sneddon a, Jennifer R. Smith c, Mary Shimoyama c, Fernando Cabral d, Charles Dumontet e, Susan K. Dutcher f, Robert J. Harvey g, Laurence Lafanechère h, John M. Murray i, Eva Nogales j, David Piquemal k, Fabio Stanchi l, Sue Povey a, Ruth C. Lovering a a HUGO Gene Nomenclature Committee, Department of Biology, University College London, Wolfson House, 4 Stephenson Way, London NW1 2HE, UK b Mouse Genomic Nomenclature Committee, Mouse Genome Informatics, The Jackson Laboratory, Bar Harbor, ME 04609, USA c Rat Genome Database, Bioinformatics Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA d Department of Integrative Biology and Pharmacology, University of Texas Medical School, Houston, TX 77030, USA e Unité Institut National de la Sante et de la Recherche Medicale 590, Laboratoire de Cytologie Analytique, Faculté de Médecine, Université Claude Bernard, 8 Avenue Rockefeller, 69373 Lyon Cedex 08, France f Department of Genetics, Washington University School of Medicine, Saint Louis, MO 63110, USA g Department of Pharmacology, The School of Pharmacy, 29-39 Brunswick Square, London WC1N1AX, UK h Centre de Criblage pour Molécules Bio-Actives, Institut de Recherches en Technologies et Sciences pour le Vivant, CEA–Grenoble, 17 Rue des Martyrs, 38054 Grenoble, France i Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, PA 19104-6058, USA j Howard Hughes Medical Institute, Molecular and Cell Biology Department, and Lawrence Berkeley National Laboratory, 355 LSA, University of California at Berkeley, Berkeley, CA 94720-3200, USA k Skuld-Tech Laboratories, Bioinformatics Center, Montpellier, France l Institute of Signaling, Developmental Biology, and Cancer Research, CNRS UMR6543, Centre A.
    [Show full text]
  • Genome-Wide Analysis of Genetic Alterations in Testicular Primary Seminoma Using High Resolution Single Nucleotide Polymorphism Arrays☆
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Genomics 97 (2011) 341–349 Contents lists available at ScienceDirect Genomics journal homepage: www.elsevier.com/locate/ygeno Genome-wide analysis of genetic alterations in testicular primary seminoma using high resolution single nucleotide polymorphism arrays☆ Cynthia LeBron a,1, Prodipto Pal a,1, Mariana Brait a, Santanu Dasgupta a, Rafael Guerrero-Preston a, Leendert H.J. Looijenga b, Jeanne Kowalski c, George Netto d, Mohammad O. Hoque a,⁎ a Johns Hopkins University, School of Medicine, Department of Otolaryngology, Head and Neck Cancer Research, Baltimore MD, USA b Erasmus MC — University Medical Center Rotterdam, Josephine Nefkens Institute (Daniel den Hoed Cancer Center), Department of Pathology, The Netherlands c Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA d Department of Pathology and Urology, Johns Hopkins Medical Institutions, MD, USA article info abstract Article history: Testicular germ cell tumors (TGCT) represent the most common malignancy among young males. To our Received 1 September 2010 knowledge no comprehensive Copy Number Variation (CNVs) studies of TGCT using high-resolution Single Available online 2 March 2011 Nucleotide Polymorphism (SNP) array have been performed. By a genome-wide analysis of CNV and loss of heterozygosity (LOH) in 25 primary seminomas, we confirmed several previously reported genomic Keywords: alterations and discovered eight novel genomic alterations including amplifications and homozygous Testicular cancer deletions. Moreover, a comparison of genomic alterations of early and late stage seminoma identified CNVs SNP array Seminoma that correlate with progression, which included deletions in chromosomes 4q, 5p, 9q, 13q and 20p and Genome-wide analysis amplifications in chromosomes 9q and 13q.
    [Show full text]
  • A Network-Based Approach to Uncover Microrna-Mediated Disease Comorbidities and Potential Pathobiological Implications
    www.nature.com/npjsba ARTICLE OPEN A network-based approach to uncover microRNA-mediated disease comorbidities and potential pathobiological implications Shuting Jin1,9, Xiangxiang Zeng2,9, Jiansong Fang3, Jiawei Lin1, Stephen Y. Chan4, Serpil C. Erzurum5,6 and Feixiong Cheng3,7,8* Disease–disease relationships (e.g., disease comorbidities) play crucial roles in pathobiological manifestations of diseases and personalized approaches to managing those conditions. In this study, we develop a network-based methodology, termed meta- path-based Disease Network (mpDisNet) capturing algorithm, to infer disease–disease relationships by assembling four biological networks: disease–miRNA, miRNA–gene, disease–gene, and the human protein–protein interactome. mpDisNet is a meta-path- based random walk to reconstruct the heterogeneous neighbors of a given node. mpDisNet uses a heterogeneous skip-gram model to solve the network representation of the nodes. We find that mpDisNet reveals high performance in inferring clinically reported disease–disease relationships, outperforming that of traditional gene/miRNA-overlap approaches. In addition, mpDisNet identifies network-based comorbidities for pulmonary diseases driven by underlying miRNA-mediated pathobiological pathways (i.e., hsa-let-7a- or hsa-let-7b-mediated airway epithelial apoptosis and pro-inflammatory cytokine pathways) as derived from the human interactome network analysis. The mpDisNet offers a powerful tool for network-based identification of disease–disease relationships with miRNA-mediated pathobiological pathways. 1234567890():,; npj Systems Biology and Applications (2019) ; https://doi.org/10.1038/s41540-019-0115-25:41 INTRODUCTION or completely pairing with their 3′ UTR region, thereby reducing The manifestation and clinical severity of human disease are the stability of the target miRNA or inhibiting translation to 9 affected by myriad factors, including genetic, epigenetic, lifestyle, downregulate the expression of genes of interest.
    [Show full text]
  • Identification of RASSF8 As a Candidate Lung Tumor Suppressor
    Oncogene (2006) 25, 3934–3938 & 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00 www.nature.com/onc ORIGINAL ARTICLE Identification of RASSF8 as a candidate lung tumor suppressor gene FS Falvella1, G Manenti1, M Spinola1, C Pignatiello1, B Conti2, U Pastorino2, TA Dragani1 1Department of Experimental Oncology and Laboratories, Istituto Nazionale Tumori, Milan, Italy and 2Unit of Thoracic Surgery, Istituto Nazionale Tumori, Milan, Italy The RASSF8 gene,which maps close to the KRAS2 In mammals, the RAS signaling pathway is mediated gene,contains a RAS-associated domain and encodes by numerous effectors, including proteins with a RAS- a protein that is evolutionarily conserved from fish associated (RalGDS/AF-6) (RA) domain (Malumbres to humans. Analysis of the RASSF8 transcript revealed and Barbacid, 2003; Wohlgemuth et al., 2005). Interest- a complex expression pattern of 50-UTR mRNA isoforms ingly, the genes C11ORF13 at 25.9kb from the HRAS1 in normal lung and in lung adenocarcinomas (ADCAs), gene on Chromosome 11 and RASSF8 (Ras association with no apparent differences. However,RASSF8 (RalGDS/AF-6) domain family 8) at 70.8 kb from the gene transcript levels were Bseven-fold-lower in lung KRAS2 gene on Chromosome 12 (http://www.ensembl. ADCAs as compared to normal lung tissue. Expression of org/Homo_sapiens/), contain a RAS (RalGDS/AF-6) RASSF8 protein by transfected lung cancer cells led to domain mapping near the two RAS genes. The presence inhibition of anchorage-independent growth in soft agar in of such domains close to RAS genes suggests the A549 cells and reduction of clonogenic activity in NCI- conservation of functional genomic fragments (Wall H520 cells.
    [Show full text]
  • The Ins and Outs of RAS Effector Complexes
    biomolecules Review The Ins and Outs of RAS Effector Complexes Christina Kiel 1,2, David Matallanas 1 and Walter Kolch 1,3,* 1 Systems Biology Ireland, School of Medicine, University College Dublin, Dublin 4, Ireland; [email protected] (C.K.); [email protected] (D.M.) 2 UCD Charles Institute of Dermatology, School of Medicine, University College Dublin, Dublin 4, Ireland 3 Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin 4, Ireland * Correspondence: [email protected]; Tel.: +353-1-716-6303 Abstract: RAS oncogenes are among the most commonly mutated proteins in human cancers. They regulate a wide range of effector pathways that control cell proliferation, survival, differen- tiation, migration and metabolic status. Including aberrations in these pathways, RAS-dependent signaling is altered in more than half of human cancers. Targeting mutant RAS proteins and their downstream oncogenic signaling pathways has been elusive. However, recent results comprising detailed molecular studies, large scale omics studies and computational modeling have painted a new and more comprehensive portrait of RAS signaling that helps us to understand the intricacies of RAS, how its physiological and pathophysiological functions are regulated, and how we can target them. Here, we review these efforts particularly trying to relate the detailed mechanistic studies with global functional studies. We highlight the importance of computational modeling and data integration to derive an actionable understanding of RAS signaling that will allow us to design new mechanism-based therapies for RAS mutated cancers. Keywords: RAS oncogene; RAS signaling networks; RAS in human cancer; targeting RAS; computa- tional modeling; personalized therapies Citation: Kiel, C.; Matallanas, D.; Kolch, W.
    [Show full text]